Skip to content

Summit Therapeutics’ study identifies DMD biomarkers

March 15, 2016

Summit Therapeutics plc (NASDAQ: SMMT LON:SUMM) has identified biomarkers to relate muscle regeneration and the presence of utrophin protein in patients with Duchenne (DMD) and Becker muscular dystrophy (BMD).

DMD is caused by the absence of dystrophin protein and it is believed utrophin modulation, a naturally occurring protein similar to dystrophin, could slow or even stop the progression of DMD.Click here to read more.